Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab plus chemotherapy for metastatic gastric or GEJ adenocarcinoma.
Marcia Cruz-Correa, MD, PhD, AGAF, FASGE
Advertisement
Articles by Marcia Cruz-Correa, MD, PhD, AGAF, FASGE
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Bexobrutideg Produces High Response Rates Across Treatment Lines in CLL/SLL
2
Osimertinib Plus Gefitinib Suppresses Acquired EGFR Resistance Mutations in First-Line NSCLC
3
FDA Accepts NDA for Bezuclastinib in Advanced Systemic Mastocytosis
4
AMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC
5